MedTrace Logo

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1

NCT00000318 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to assess optimal dosage of buprenorphine on a thrice weekly schedule in a pilot clinical trial.

Conditions

  • Opioid-Related Disorders
  • Substance-Related Disorders

Interventions

DRUG

Buprenorphine

1. Experimental Maintenance treatment with daily medication 2. Experimental Maintenance treatment with thrice-weekly medication

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Richard Schottenfeld, M.D. · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-12-31
Primary Completion
2004-03-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000318 on ClinicalTrials.gov